Safety Reading Notes

Read safety context beside the research guide.

The CBGV source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 35648593

PubMed For Dummies Article

CBGV Evidence Review: the long-form source walk-through

Quick read
  • CBGV currently has 22 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 35648593
  • The evidence classes most visible in the row language are mechanistic or pharmacological (12), insufficient (9), and preclinical (1). PMID 42163693
  • The study-design language most visible in the row language is Animal study (8), Cellular or in vitro study (6), and Narrative or expert review (1). PMID 34617621
  • The repeated topics are Rare phytocannabinoids research topics (7), Skin and inflammatory dermatology (3), receptor, target, or pharmacology mechanisms (2), receptor, target, metabolic, or pharmacology mechanisms (2), and other mapped categories (8), which tells the reader where to start opening PubMed and DOI links. PMID 36827690

Start with the research question

CBGV is built from 22 source-backed evidence row(s) and 14 research source(s). The current evidence classes read as mechanistic or pharmacological (12), insufficient (9), and preclinical (1), and the study-design language most often reads as Animal study (8), Cellular or in vitro study (6), and Narrative or expert review (1). PMID 35648593

The row-level question is not simply whether CBGV is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Rare phytocannabinoids research topics (7), Skin and inflammatory dermatology (3), receptor, target, or pharmacology mechanisms (2), receptor, target, metabolic, or pharmacology mechanisms (2), and other mapped categories (8). PMID 21175579

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 38885660

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 36770831

Mechanistic evidence 10 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 34078070

Limits and uncertainty 12 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 38940871

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 34384142

Where this page has the most source density

The largest bucket surfaced for this page is Rare phytocannabinoids. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Receptor, target, metabolic, and pharmacology mechanisms, which gives readers another way to see what the literature repeatedly circles. PMID 35648593

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 21175579

Bucket chapters: what the literature is circling

Rare phytocannabinoids

3 research sources 3 rows (249-252) Mapped evidence with interpretation limits: insufficient (3)

CBGV appears in rows studying Rare phytocannabinoids. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 35648593

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 35648593

  • Evidence row 249

    THC studied for Rare phytocannabinoids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Rare phytocannabinoids research topics). PMID 35648593

  • Evidence row 252

    THC studied for Rare phytocannabinoids research topics; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: Rare phytocannabinoids evidence... PMID 38940871

Receptor, target, metabolic, and pharmacology mechanisms

2 research sources 2 rows (765-780) Mechanistic research summary: mechanistic or pharmacological (2)

CBGV appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 2 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 21175579

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 21175579

  • Evidence row 765

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure:... PMID 21175579

  • Evidence row 780

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target,... PMID 21726418

Skin and inflammatory dermatology

2 research sources 2 rows (700-707) Mechanistic research summary: mechanistic or pharmacological (2)

CBGV appears in rows studying Skin and inflammatory dermatology. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 42163693

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 42163693

  • Evidence row 700

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin,... PMID 42163693

  • Evidence row 707

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin,... PMID 27094344

Pain-related outcomes

1 research source 697 Mechanistic research summary: mechanistic or pharmacological (1)

CBGV appears in rows studying Pain-related outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36551296

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 36551296

  • Evidence row 697

    CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 36551296

Rare phytocannabinoids

1 research source 251 Mapped evidence with interpretation limits: insufficient (1)

CBGV appears in rows studying Rare phytocannabinoids. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 34078070

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 34078070

  • Evidence row 251

    CBC studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics). PMID 34078070

Rare phytocannabinoids

1 research source 246 Mapped evidence with interpretation limits: insufficient (1)

CBGV appears in rows studying Rare phytocannabinoids. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 34617621

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 34617621

  • Evidence row 246

    CBD studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics). PMID 34617621

Rare phytocannabinoids

1 research source 248 Mapped evidence with interpretation limits: insufficient (1)

CBGV appears in rows studying Rare phytocannabinoids. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 38885660

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 38885660

  • Evidence row 248

    CBG studied for Rare phytocannabinoids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Rare phyto... PMID 38885660

Rare phytocannabinoids

1 research source 247 Mapped evidence with interpretation limits: insufficient (1)

CBGV appears in rows studying Rare phytocannabinoids. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36827690

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 36827690

  • Evidence row 247

    HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics). PMID 36827690

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (10 row(s)), and safety/tolerability context (3 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 35648593

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 21175579

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 35566314
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 21175579
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 27094344

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 35648593

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 21175579

Source-reading checklist for CBGV

  1. Open the linked PubMed or DOI record. PMID 36551296
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 21726418
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 35648593
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 42163693
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 34617621

Source Notes

CBGV source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 161

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 42163693

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
  2. Evidence row 246

    CBD studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics). PMID 34617621

    Evidence class: insufficient. Source: Calculated and experimental 1 H and 13 C NMR assignments for cannabicitran.
  3. Evidence row 247

    HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics). PMID 36827690

    Evidence class: insufficient. Source: Isolation and Characterization of Impurities in Commercially Marketed Δ8-THC Products.
  4. Evidence row 248

    CBG studied for Rare phytocannabinoids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: Rare phytocannabinoids research topics). PMID 38885660

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion.
  5. Evidence row 249

    THC studied for Rare phytocannabinoids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Rare phytocannabinoids research topics). PMID 35648593

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa.
  6. Evidence row 250

    THC studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics). PMID 36770831

    Evidence class: insufficient. Source: Chiral Separation of Cannabichromene, Cannabicyclol, and Their Acidic Analogs on Polysaccharide Chiral Stationary Phases.
  7. Evidence row 251

    CBC studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics). PMID 34078070

    Evidence class: insufficient. Source: Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog.
  8. Evidence row 252

    THC studied for Rare phytocannabinoids research topics; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: Rare phytocannabinoids research topics). PMID 38940871

    Evidence class: insufficient. Source: A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol.
  9. Evidence row 280

    CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34384142

    Evidence class: preclinical; Study design: Animal study. Source: Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
  10. Evidence row 287

    THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 35566314

    Evidence class: insufficient. Source: Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures.
  11. Evidence row 325

    THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 38940871

    Evidence class: insufficient. Source: A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol.
  12. Evidence row 364

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  13. Evidence row 619

    CBG studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 27094344

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.
  14. Evidence row 636

    CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42163693

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
  15. Evidence row 697

    CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 36551296

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain.
  16. Evidence row 700

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 42163693

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
  17. Evidence row 707

    CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 27094344

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.
  18. Evidence row 765

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  19. Evidence row 780

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21726418

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
  20. Evidence row 1008

    THC modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 21726418

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
  21. Evidence row 1019

    THC modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 21726418

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
  22. Evidence row 1050

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.